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cense. httpAbstract Overview: Although angiomyolipoma (AML) is a relatively rare entity, it is the most
common benign mesenchymal neoplasm of the kidney.
The aim of this study: To highlight the clinicopathological characteristics of AML and to assess the
role of Human Melanoma Black-45 (HMB-45), Melan-A, smooth muscle actin (SMA), S-100 and
cytokeratin in its diagnosis.
Materials and methods: The study included 15 cases of AML. Clinical and radiological data were
retrieved from the archival ﬁles and all cases were subjected to a histopathological evaluation as well
as immunohistochemical staining for HMB-45, Melan-A, SMA, S-100, and cytokeratin.
Results: AML was more common in females (female:male = 4:1), the mean age was
53.9 ± 6.45 years. 60% of patients were symptomatic while the remaining 40% were asymptomatic.
A statistically signiﬁcant relationship was found between size of the tumor and the presence of the
symptoms (P= 0.02). Patients with tumor size less than 4 cm were asymptomatic, while those with
tumor size larger than 4 cm had different symptoms.
Thirteen cases were classic AML, while 2 cases were epithelioid AML. Classic AML demonstrated
admixture of fatty tissue, thick-walled blood vessels, and smooth muscle, while epithelioid AMLHMB-45, Human Melanoma
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126 G.E.S. Esheba, N.E.S. Eshebawas composed mainly of epithelioid cells and contained no fat. HMB-45 was positive in all cases of
AML (100%), Melan-A was positive in 13/15 (87%) while SMA was positive in 11/15 (73%) of
AML with variable staining intensity. All cases of AML were negative for S-100 and cytokeratin.
Conclusion: AMLs have characteristic clinicopathological and immunohistochemical features and
their recognition is crucial for proper diagnosis and treatment.
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Angiomyolipoma belongs to a family of neoplasms called per-
ivascular epithelioid cell tumors (PEComas) [1–8]. The World
Health Organization (WHO) deﬁnes PEComas as ‘‘mesenchy-
mal tumors composed of histologically, ultra structurally, and
immunohistochemically distinctive perivascular epithelioid
cells C [9]. PEComas are a family of related mesenchymal neo-
plasms that include angiomyolipoma (renal and extrarenal
variants), lymphangiomyomatosis, clear cell ‘sugar’ tumor of
the lung, clear cell myomelanocytic tumor (CCMMT) of the
falciform ligament/ligamentum teres, primary extrapulmonary
‘‘sugar’’ tumor and clear cell tumors of diverse sites [10–17].
All these tumors share a distinctive cell type, the perivascu-
lar epithelioid cell or ‘PEC’ (which has no known normal tissue
counterpart). The perivascular epithelioid cell (PEC) is a ‘‘no-
vel’’ cell type showing morphologic, immunohistochemical,
ultrastructural, and genetical distinctive features, such as an
epithelioid appearance with a clear to granular cytoplasm, a
round to oval, centrally located nucleus and an inconspicuous
nucleolus, and a typical perivascular location [11–16]. Immu-
nohistochemically, PEC expresses myogenic and melanocytic
markers, such as HMB-45, Melan-A/Mart1, smooth muscle
actin and, less commonly, desmin [18,19].
HMB-45 is a monoclonal antibody that reacts against an
antigen present in melanocytic tumors and stands for Human
Melanoma Black. The speciﬁc antigen recognized by HMB-45
is now known as Pmel 17.
HMB-45 is nonreactive with almost all non-melanoma hu-
man malignancies, with the exception of rare tumors showing
evidence of melanogenesis (e.g., pigmented schwannoma, clear
cell sarcoma, and PEComas) [20].
The Melan-A gene, also known as MART-1 (Melanoma
Antigen recognized by T-cells), was cloned from a melanoma
cell line. Two monoclonal antibodies have been raised; A103
and M2-7C10. A103 has been the most extensively studied in
histological material; MC-7C10 has been studied mainly in
cytological preparations [21].
At ultrastructural analysis, PEC contains microﬁlament
bundles with electron-dense condensation, numerous mito-
chondria and membrane-bound dense granules [7].
In 1991, following reports of HMB-45 immunoreactivity
and the presence of premelanosomes in both clear cell ‘sugar’
tumor (CCST) of the lung and the epithelioid clear cell compo-
nent of angiomyolipoma (AML) of the kidney and liver, Bone-
tti et al. ﬁrst proposed a cellular link between these unusual
mesenchymal lesions and lymphangiomyomatosis (LAM)
[22]. Soon after, the same group suggested the descriptive term
‘perivascular epithelioid cell’ (PEC) for the distinctive cell type
found in these three lesions, and hypothesized that the so-
called PEC may originate from the walls of blood vessels,based upon the observation that these cells are frequently inti-
mately related to such structures [23].
In 1996, Zamboni et al., reported the ﬁrst case of pancreatic
clear cell sugar tumor and suggested to name PEComa for
those neoplasms composed by a pure proliferation of PECs
[24].
PEComas of the kidney include classic AML, microscopic
AML (so-called microhamartoma), intraglomerular lesions,
cystic AML, epithelioid AML, oncocytoma-like AML and
lymphangiomyomatosis of the renal sinus [7].
Although most often sporadic, renal AML is highly associ-
ated with the tuberous sclerosis complex (TSC), a group of
autosomal dominant genetic disorders caused by germ-line
mutations in the TSC1 or TSC2 genes located on chromo-
somes 9q and 16p, which encode the proteins hamartin and
tuberin, respectively [7,25] .
Angiomyolipoma, for a long time, has been considered as a
hamartoma rather than a true neoplasm, but at present, its clo-
nal nature has been demonstrated [26]. Green et al. [27] and
Paradis et al. [28] have shown that renal angiomyolipomas
have nonrandom inactivation of the X chromosome suggesting
clonal origin. Many cases of sporadic angiomyolipoma also
show loss of the TSC2 locus on chromosome band 16p13, or
other clonal chromosomal aberrations [29].
The origin of PEComa is still controversial; one current
hypothesis is that the neoplasm derives from undifferentiated
cells of the neural crest with smooth muscle and melanocytic
phenotype. A second hypothesis is that PEC has a myoblastic,
smooth muscle origin with a molecular alteration that leads to
the expression of melanogenesis and melanocytic markers; a
third hypothesis is that PEC has a pericytic origin [7,30].
The pathogenesis of PEComas is still not completely under-
stood and is being explored owing to their rarity. However
inactivation of TSC1 and/or TSC2 genes, with subsequent acti-
vation of mammalian target of mTOR pathway has been asso-
ciated with the pathogenesis of both syndromic and sporadic
PEComas [7,31–33].
Materials and methods
A total of 15 cases of AML were studied in this work. 13 cases
were obtained retrospectively, from the archives of the Depart-
ment of Pathology, Faculty of Medicine, Tanta University
during the period between 2000 and 2012, while 2 cases (cases
number 7 and 8) were selected from the wards of the internal
medicine department, Tanta University hospital during the
period between October 2011 and January 2013. The two cases
were admitted for treatment of anemia caused by frank hema-
turia; and they were subjected to the following: informed
written consent, thorough history taking, clinical examination
both general and local, routine laboratory investigations:
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and 2 h postprandial blood glucose, complete lipid proﬁle.
Imaging studies: abdominal ultrasound, abdominal CT and
abdominal MRI if needed.
All available clinical data for each case including age, gen-
der, symptoms, type of the surgical procedure, radiological
ﬁndings, and tumor size, were obtained from the accompany-
ing clinical sheets. Parafﬁn blocks were obtained and sec-
tioned. The slides were stained with H&E to conﬁrm the
histological diagnosis.
Classiﬁcation of AMLs
In this study, AMLs were classiﬁed as classic and epithelioid
according to the 2004 World Health Organization classiﬁca-
tion of tumors [9]. Classic AMLs were diagnosed when the tu-
mor is composed of a variable proportion of adipose tissue,
smooth muscle cells, and abnormal thick-walled blood vessels
and all 3 components were readily identiﬁed. While epithelioid
AMLs (EAMLs) were diagnosed when the tumors show prolif-
eration of predominantly epithelioid cells.
Pathological parameters
Tumor size was recorded according to the largest tumor diam-
eter either by radiological ﬁndings or by gross examination. The
percentage of adipose tissue, smooth muscle, blood vessels, and
epithelioid components was recorded for all cases of AML.
The following pathological parameters were also evaluated:
tumor necrosis, hemorrhage, lymphovascular, and perineural
invasion.
Immunohistochemistry
Immunohistochemical assays were performed using the follow-
ing antibodies: HMB-45, Melan-A, smooth muscle actin, S-
100, and cytokeratin. The details of primary antibodies are
summarized in Table 1.
For immunohistochemical staining 4 lm parafﬁn tissue sec-
tions were deparafﬁnized in xylene and rehydrated in descend-
ing ethanol concentrations to distilled water. Subsequently,
antigen retrieval in the tissue sections was achieved by placing
them in a Coplin jar ﬁlled with 0.01 M citrate buffer, pH 6.0,
and boiling for 5 min in a microwave oven at 600 W. The sec-
tions were then cooled to room temperature, equilibrated in
phosphate buffer solution (PBS), pH 7.4, for 10 min and trea-
ted with 0.3% H2O2 in methanol to block endogenous perox-
idase activity. Nonspeciﬁc antibody binding sites were blocked
by 30 min of incubation with normal mouse serum. The pri-
mary antibodies were applied for 2 h at room temperature.
Secondary goat anti-mouse antibody (Labvision) and strepta-
vidin–biotin–peroxidase complex were used, each for 1 h. TheTable 1 Characteristics of antibodies used for evaluation.
Antibody Clone
Melanoma Monoclonal HMB 45
Melan A Clone A103
Smooth muscle actin Monoclonal 1A4
S-100 Polyclonal
Cytokeratin Monoclonal AE1/AE3sections were washed thoroughly in PBS after each antibody
incubation. Peroxidase activity was detected using 0.05%
diaminobenzidine containing 0.01% H2O2 and counterstaining
with hematoxylin. Negative controls obtained by the use of
non-immune normal mouse serum as the primary antibody.
Positive controls consisted of sections from malignant mela-
noma (HMB-45 and Melan-A), leiomyoma (smooth muscle
actin), and normal human tonsil (cytokeratin).
Scoring methods
The staining for all markers was scored as strong (3), moderate
(2), weak (1), or negative (0). Cytoplasmic staining was scored
as positive for HMB-45, Melan-A, smooth muscle actin, and
cytokeratin; while nuclear staining was considered positive
for S-100.
Statistical analysis
Qualitative data were presented as number and percentage.
Chi-square was used to test the relation between the presence
or absence of symptoms and tumor size. Quantitative data
were presented as mean and standard deviation. P value below
0.05 was considered statistically signiﬁcant. All analyses were
performed using SPSS statistical software (SPSS V.16, Inc.,
Chicago, IL).
Results
A total of 15 cases of AML were studied in this work, 13 cases
were diagnosed as classic AML while 2 cases were epithelioid
AML (cases 14 and 15).
The clinicopathological parameters in AML cases were
listed in Table 2.
Clinical data
Twelve patients were females while the remaining 3 cases were
males; female: male ratio was 4:1. The age of the patients ran-
ged from 43 to 64 years with a mean age of 53.9 ± 6.45 years.
In this work, 9 cases (60%) were symptomatic; some pa-
tients presented by more than one symptom, while the remain-
ing 6 patients (40%) were asymptomatic and were identiﬁed
incidentally during medical examinations for other diseases
(Table 3). None of the patients had a history of tuberous
sclerosis.
There was a statistically signiﬁcant relationship between
size of the tumor and the presence of the symptoms
(P= 0.02). 6 patients (40%) with tumor size less than 4 cm
(2.68 ± 0.78 cm) were asymptomatic, while the remaining 9
patients with tumor size larger than 4 cm (4.71 ± 0.9 cm)
had different symptoms.Dilution Source
1:100 Biogenex, San Ramon, CA
1:40 DAKO, Carpinteria, CA
1:50 Biogenex, San Ramon, CA
1:1600 DAKO, Carpinteria, CA
1:50 DAKO, Carpinteria, CA
Table 2 Clinicopathological characteristics of the AML cases.
Case no. Sex Age Tumor
size
Symptoms Surgical procedure Diagnosis Imaging study done Tumor location HMB-45 Melan-A SMA S-100 CK
1 F 54 1.2 Asymptomatic Partial nephrectomy Classic AML U/S Single, Rt. kidney + + +  
2 F 45 1.5 Asymptomatic Partial nephrectomy Classic AML U/S Single, Lt. kidney + + +  
3 F 59 1.8 Asymptomatic Partial nephrectomy Classic AML U/S Single, Rt. kidney + + +  
4 M 58 2 Asymptomatic Partial nephrectomy Classic AML U/S Single, Rt. kidney +  +  
5 F 61 2.7 Asymptomatic Partial nephrectomy Classic AML U/S Single, Rt. kidney + +   
6 F 64 3.28 Asymptomatic CT guided biopsy Classic AML U/S, CT, and MRI Multifocal and bilateral +  +  
7 F 57 4 Hematuria and
anemia
CT guided biopsy followed
by arterial embolization
Classic AML U/S, CECT, and MRI Multifocal, Rt., kidney + +   
8 F 51 4.2 Hematuria and
anemia
CT guided biopsy followed
by arterial embolization
Classic AML U/S, CT, and MRI Single, Lt. kidney + + +  
9 M 52 4.5 Flank pain Partial nephrectomy Classic AML U/S Single, Lt. kidney + + +  
10 F 48 5 Hypertension
and ﬂank pain
Partial nephrectomy Classic AML U/S Single, Rt. kidney + +   
11 M 64 5.5 Hematuria Partial nephrectomy Classic AML U/S and CT Single, Lt. kidney + + +  
12 F 43 6 Hypertension Radical nephrectomy Classic AML No radiological reports Single, Rt. kidney + + +  
13 F 49 5.2 Hypertension Radical nephrectomy Classic AML No radiological reports Single, Lt. kidney + + +  
14 F 56 5.4 Hematuria and
anemia
CT guided biopsy followed
by arterial embolization
Epithelioid AML U/S, CT, and MRI Single, Rt. kidney + + +  
15 F 48 5.6 Hematuria and
anemia
Radical nephrectomyy Epithelioid AML U/S, CT, and MRI Single, Rt. kidney + +   
U/S, ultrasound; CT, computed tomography; MRI, Magnetic Resonance Imaging; CECT, contrast-enhanced CT; Rt., right; Lt., left.
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Table 3 Clinical presentation of AML patients.
Clinical presentation Number of patients Percentage (%)
Hematuria 5 33
Anemia 4 26.7
Hypertension 3 20
Flank pain 2 13
Asymptomatic 6 40
Table 4 Different procedures performed to manage the
patients.
The procedure Number of patients Percentage (%)
Partial nephrectomy 8 53.3
Radical nephrectomy 3 20
CT guided biopsy 1 6.67
CT guided biopsy followed
by arterial embolization
3 20
Table 5 Imaging techniques performed to the patients.
Imaging technique Number of patients Percentage (%)
Ultrasound 13 86.67
Plain CT 5 33.3
MRI 5 33.3
CT and MRI 4 26.67
Contrast enhanced CT
and MRI
1 6.67
Figure 1 Post contrast CT scan of the abdomen (case 6) showing
both enlarged kidneys with multiple hypodense lesions most of
them displaying fat density with the largest one in left kidney
measuring 32.8 · 32.6 mm.
Figure 2 MRI of the abdomen (case 6) showing multiple
variable sized rounded focal lesions seen in the cortex of both
kidneys.
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listed in Table 4. Three patients (cases 7, 8, and 14) underwent
arterial embolization to prevent hemorrhagic complications.
The imaging techniques performed to the patients are sum-
marized in Table 5. There were two patients who had no radio-
logical records (cases 12 and 13).
Classic AML
Ultrasonic examination revealed well circumscribed echogenic
masses.
The plain CT scan showed well-marginated heterogeneous
tumors with predominantly fatty attenuation with negative
CT number. The average attenuation depended on the relative
proportions of fat and other soft tissue in the angiomyoli-
poma. Both contrast-enhanced CT and MRI were performed
in case number (6) which was multifocal and bilateral. Con-
trast-enhanced CT showed well circumscribed hypodense le-
sions in both kidneys displaying fat density with the largest
one in left kidney measuring 32.8 · 32.6 mm (Figure 1). Simi-
larly, MRI conﬁrmed CT ﬁndings and showed high signal
intensity focal lesions in the cortex of both kidneys (Figure 2).
The characteristic appearances of angiomyolipomas with
MRI include variable areas of high signal intensity within
the tumor on both T1-weighted and T2-weighted images. On
a non-enhanced T1-weighted image, high signal intensity is
present because of the fat content. On T2-weighted images,
the signal remains iso-intense relative to that of perinephric fat.
Epithelioid AML
CT of both cases of epithelioid AML showed isolated hetero-
geneous renal masses devoid of fat densities. MRI supported
the CT ﬁndings and both cases were considered suspicious
for renal cell carcinoma.
Pathological ﬁndings
Classic AML (13 cases)
The mean size of all AML cases was 3.9 ± 1.32 cm; the mean
size of classic AML was 3.6 ± 1.14 cm (range 1.2–6 cm).11/13 (84.6%) cases of classic AML showed a single mass (6
cases affected the right kidney and 5 cases affected the left
one). Case 6 was multifocal and bilateral; the largest tumor
was in the left kidney and measured 3.28 cm by CT. Case 7
Figure 3 Classic AML showing well circumscribed tumor (40·).
Figure 4 Classic AML composed of an admixture of thick-
walled blood vessels, mature adipose tissue, and smooth muscle,
the latter forming vascular cufﬁng around blood vessels (100·).
Figure 5 Epithelioid AML showing epithelioid smooth muscle
cells around blood vessels, focal nuclear atypia is seen (arrow)
(400·).
Table 6 Expression pattern of HMB-45, Melan-A, smooth
muscle actin, S-100 and cytokeratin in AMLs.
Marker No. % Scoring of immunoreactivity
0 +1 +2 +3
HMB-45 15/15 100 0 0 2 13
Melan-A 13/15 87 2 1 4 8
Smooth muscle actin 11/15 73 4 3 5 3
S-100 0/15 0 15 0 0 0
Cytokeratin 0/15 0 15 0 0 0
130 G.E.S. Esheba, N.E.S. Eshebawas multifocal within the right kidney; the largest mass was
4 cm as measured by CT.
Gross pathology
The tumors showed non-inﬁltrative, well-circumscribed and
non-encapsulated soft tissue masses. The cut surfaces of tu-
mors were yellow brown or dark brown according to the per-
centage of the 3 components. All cases showed no hemorrhage
or necrosis.
Microscopic examination
At scanning magniﬁcation, the lesions were well circumscribed
in all cases (Figure 3).
AML was composed of an admixture of blood vessels,
smooth muscle, and mature adipose tissue of varying propor-
tions and distributions. A subset of the smooth muscle cells
was spindle, while others were epithelioid in appearance and
showed clear to palely eosinophilic granular cytoplasm, a cen-
tral located round to oval nucleus with inconspicuous nucleoli,
no atypia, and no mitotic ﬁgures. The epithelioid and spindle
muscle cells formed vascular cufﬁng around the blood vessel.
The blood vessels were thick-walled and often hyalinized (Fig-
ure 4), many thin wall veins or blood sinuses were diffused in
the tumor parenchyma.No necrosis was detected; however, hemorrhage was seen in
2 cases (15.4%) (cases 7 and 8). There were no vascular or per-
ineural invasion.
Epithelioid AML (2 cases)
Both cases were in the right kidney. Case (14) was subjected to
CT guided needle biopsy followed by arterial embolization and
measured 5.4 cm. Case (15) underwent radical nephrectomy. It
measured 5.6 cm and its cut surface was brown and friable
with focal necrosis and hemorrhage.
At scanning magniﬁcation, case (15) appeared inﬁltrative
with irregular edges.
Both cases demonstrated proliferation of predominantly
epithelioid cells with abundant granular cytoplasm arranged
around thick walled blood vessels. No fatty tissue was seen.
The tumor cells had enlarged vesicular nuclei and prominent
nucleoli with focal nuclear atypia (Figure 5) and mitotic ﬁgures
[one mitotic ﬁgure per 10 high power ﬁeld (HPF)].
Focally, the cells had a nested, trabecular, or sheet-like
growth pattern.
Both cases showed hemorrhage. Case (15) also showed areas
of necrosis, there were no vascular or perineural invasion.
Immunohistochemistry
The detailed immunohistochemical characteristics that were
observed in AMLs using HMB-45, Melan-A, SMA, S-100
and cytokeratin are summarized in Table 6.
HMB-45 was positive in all cases of AML (100%), Melan-
A was positive in 13/15 (87%) while SMA was positive in 11/
15 (73%) of Figure 6.
Figure 6 AML demonstrating strong cytoplasmic staining for HMB-45 (a) (400·), Melan-A (b) (400·), and smooth muscle actin (c)
(100·).
Angiomyolipoma of the kidney: Clinicopathological and immunohistochemical study 131S-100 and cytokeratin were done to exclude melanoma and
renal cell carcinoma and all cases were negative for both
markers.
All 13 cases of classic AML (100%) showed positive cyto-
plasmic immunoreactivity for HMB-45 while 11/13 cases
(85%) were positive for Melan-A. SMA was positive in 10/
13 (77%) of cases.
Both cases of epithelioid AML exhibited strong staining for
HMB-45 and Melan-A. One case was negative for SMA, while
the second case demonstrated weak staining for SMA.
Discussion
Classic renal angiomyolipoma is one of the most common be-
nign renal lesions of the kidney, comprising 2.0–6.4% of all re-
nal tumors and approximately 1% of surgically removed renal
tumors. [9,34,35].
Epidemiologically, AML has a distinct female predomi-
nance, as observed in our study (female: male = 4:1). This ﬁnd-
ing was consistent with previously published studies [5,9].
However,Yang et al. [1] reported that female:male ratiowas 2:1.
The patients were in the fourth to sixth decades of life, with
a mean age of 53.9 ± 6.45 years. Concomitant ﬁnding was
previously reported [1,5,9]. Martignoni et al. stated that the
mean age at diagnosis of AML in surgical series is between
45and 55 for patients without TS [9].
60% of AML cases in this study were symptomatic. The
clinical manifestations included hematuria (33%), anemia
(26.7%), hypertension (20%), and ﬂank pain (13%). A similar
ﬁnding was previously reported by Pode et al. [36], Yamakadoel al. [37], and Sooriakumaran et al. [38]. The former authors
also found that the most severe symptoms were associated with
rupture of the tumor and mentioned that patients with rup-
tured angiomyolipoma often present acutely with pain as a re-
sult of hemorrhage and up to 20% are in shock at the time of
initial presentation, while Yamakado et al. [37] reported that
there are signiﬁcant relationships between tumor size and rup-
ture in angiomyolipomas and added that tumor size is the
main predictor of hemorrhage.
In this work, we found a statistically signiﬁcant relationship
between the size of the tumor and the presence of the symp-
toms (P= 0.02). Patients with tumor size more than 4 cm
tended to be symptomatic, while those with tumor size less
than 4 cm were asymptomatic. These results conﬁrm those pre-
viously reported by Dickinson et al. [39].
In our current study, renal AMLs had clearly deﬁned radio-
logical characteristics. Classic AML by ultrasound appeared as
a well-deﬁned echogenic lesion. Similar ﬁnding was previously
documented by Siegel et al. [40] who also mentioned that renal
angiomyolipomas are intensely echogenic masses and a reduc-
tion of echogenicity in AMLs is related to a decrease in the
quantity of fat and/or an increase in the amount of myogenic
components.
In this work, unenhanced CT demonstrated the presence of
fat in classic AML. Fat appeared as hypodense tissue. These
results were concomitant with those of Halpenny et al. [41],
who further concluded that attenuations of less than
20 Hounsﬁeld units (HU) are widely accepted as conﬁrming
the presence of fat and this ﬁnding virtually conﬁrms the diag-
nosis of angiomyolipoma.
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fat in CT and MRI and therefore, RCC was suspected. This
ﬁnding conﬁrms and extends those previously reported by Var-
ma et al. [8], Tsai et al. [35], and Lane et al. [42]. On the con-
trary, it is contradicted with that of Chen et al. [43] who
reported a case of aggressive epithelioid AML which showed
fat by both CT and MRI.
It is sometimes difﬁcult to differentiate AML with minimal
fat from RCC. Kim et al. [44] identiﬁed some CT scan ﬁndings
valuable for differentiating angiomyolipoma with minimal fat
from renal cell carcinoma including homogeneous tumor
enhancement, prolonged enhancement pattern, and high tu-
mor attenuation on unenhanced scans in AMLs.
None of the patients in this study had a history of TSC.
AMLs in patients with TSC have no sex predilection, in the
third and fourth decades of life, they are usually asymptom-
atic, usually bilateral, small and multifocal. Sporadic AMLs
occur in older patients, with a female predominance; they are
single, unilateral and larger than those associated with TSC [7].
All but 2 cases of classic AML (11/13, 85%) in this work
were unilateral and solitary. Whereas the other 2 cases of clas-
sic AML were multifocal, and one of them was bilateral. Both
cases showed the typical triphasic pattern. This ﬁnding is in
keeping with those of Varma et al. [8], who also stated that
classic renal angiomyolipomas may have locoregional or mul-
ticentric involvement; however, these lesions have always be-
haved in a benign manner and have not been associated with
an adverse prognosis. Similarly, Yang et al. [1] in their study
found that 6/122 of the classic renal AML cases presented with
multiple foci. Two of the cases had foci located in the bilateral
kidney as well. Moreover, Brimo et al. [45] reported that classic
AML is considered to be benign even in the presence of vascu-
lar or regional lymph node involvement, which is regarded as
indicative of multifocal growth, rather than aggressive
behavior.
In this work, all cases of classic AML were positive for
HMB-45, (100%), Melan-A was positive in 85% of cases,
while SMA was positive in 73%. All classic AML cases were
negative for S-100 and cytokeratin. Similar results have been
reported by most, but not all other investigators [1,4–9]. Kim
et al. [46], on the other hand, reported that S-100 was positive
in 8/10 classic AML cases. However, this variation could be
attributed to the use of different antibody clones in their study.
Two cases in this study were diagnosed as an epithelioid
angiomyolipoma. The tumors were composed mainly of epi-
thelioid cells with focal nuclear pleomorphism, prominent
nucleoli, and mitoses. No fatty tissue was identiﬁed. Necrosis
was seen in one case, while hemorrhage was present in both
cases. Both cases showed strong cytoplasmic staining for
HMB-45 and Melan-A. SMA was negative in one case and
weakly positive in the second one. Both cases were negative
for S-100 and cytokeratin. Similar ﬁndings were documented
by Varma et al. [8], Tsai et al. [35], and Aydin et al. [47]. On
the contrary; Yang et al. [1] reported strong SMA and actin
in epithelioid AML and moderate HMB-45 staining.
Varma et al. [8] and Tsai et al. [35] mentioned that epithe-
lioid AML can resemble sarcomatoid RCC and metastatic
melanoma, therefore, the ﬁnal diagnosis is established based
on the presence of positive reaction for HMB-45, Melan-A
and SMA and negative reaction for S-100 and cytokeratin.
The epithelioid variant of renal angiomyolipoma is a re-
cently described entity that has been recognized in the 2004WHO classiﬁcation of renal tumors and shows a high degree
of association with tuberous sclerosis, and demonstrates
aggressive behavior unlike classic renal angiomyolipomas,
which are commonly benign [48].
In otherwise classic AML, areas of epithelioid cells can be
observed, raising the question how much of these epithelioid
cells should be present to call a tumor ‘‘epithelioid angiomyo-
lipoma’’. There is no deﬁnite cut off point for the exact amount
of epithelioid cells that should be present. Lane et al. [42] pro-
posed that more than 95% of the tumor should contain epithe-
lioid cells to call it epithelioid AML, while Yang et al. [1]
reported that the epithelioid component in their study ac-
counted for 90% of the tumor. On the other hand, the
WHO states that ‘‘epithelioid AML is a potentially malignant
mesenchymal neoplasm characterized by proliferation of pre-
dominantly epithelioid cells’’, however, the extent of the epi-
thelioid component that warrants the designation of a tumor
as epithelioid AML has not been established [48].
Therefore, Martignoni et al. suggested a consensus meeting
to address this issue [7].
Martignoni et al. [49] ﬁrst described the epithelioid variant
of renal angiomyolipoma in 1994. The authors described 7
cases of renal tumors composed of sheets of bizarre oxyphilic
epithelioid cells, having large nuclei with prominent nucleoli,
uniformly positive for HMB-45, focally positive for actin
and negative for keratin and epithelial membrane antigen.
Prior to the identiﬁcation of this variant, many cases were
misdiagnosed as renal cell carcinomas. Pea et al. [50] reexam-
ined the tissue parafﬁn blocks and slides from 5 different cases
of tuberous sclerosis-associated renal cell carcinomas and re-
classiﬁed 3 cases as ‘‘epithelioid variant of angiomyolipoma,’’
based on HMB-45 immunoreactivity and negative cytokeratin
immunostaining and the authors suggested that the increased
incidence of RCC associated with TSC may be due to incorrect
classiﬁcation of EAML as RCC.
Approximately 30% of epithelioid AMLs (EAMLs) have
malignant potential [35]. Therefore, in 2010, Brimo et al. [45]
proposed the concept of atypical EAMLs, and suggested that
certain atypical morphological features may be correlated with
malignant behavior. Those features include: more than 70%
atypical epithelioid cells; more than 2 mitotic ﬁgures per 10
HPF; atypical mitotic ﬁgures; and necrosis. Additionally, these
authors concluded that the presence of three or more of the
above features predicts an increased risk of clinically malig-
nant behavior. In our study, the percentage of atypical epithe-
lioid cells were much lower than 70%, the mitotic count was
less than 2/10 HPF, and there was no abnormal mitotic ﬁgures.
Only one case showed necrosis. Based on these criteria, the 2
cases of epithelioid AML in this work do not qualify as atyp-
ical epithelioid AML.
Tsai et al. [35] mentioned that the diagnosis of AML can
sometimes be established by imaging alone, but CT-guided
percutaneous biopsy (2–5 cores) is sometimes necessary if no
fat is detected and RCC is suspected as in case no. 14 in this
work.
The management of renal AMLs is widely discussed in the
literature [8,31,35,42,51,52] and is primarily based on clinical
presentation, the size of the tumor, bilaterality, and malignant
potential. Thus, in asymptomatic tumors, evaluation with
abdominal ultrasound and/or CT-scan every six or twelve
months, depending on the size of the tumor, greater or less
than 4 cm, respectively, is necessary. In symptomatic and/or
Angiomyolipoma of the kidney: Clinicopathological and immunohistochemical study 133bilateral tumors, artery embolization, selective kidney or con-
servative surgery (nephron sparing) are the treatments of
choice. Radical nephrectomy is reserved for those cases with
hemodynamic instability due to massive bleeding, large tu-
mors, or if RCC is suspected [42].
Because approximately one third of cases of EAML show
advanced disease, it is essential to initiate appropriate treat-
ment with close follow-up, as for RCC, owing to its malignant
potential [35].
Currently, there is no known effective therapy for epitheli-
oid angiomyolipoma other than surgery [8]. Metastatic EAML
has been treated with a variety of chemotherapeutic agents
including doxorubicin, dacarbazine, ifosfamide, cyclophospha-
mide and cisplatin [51]. As mentioned earlier, Kenerson et al.
[31] found that epithelioid angiomyolipomas uniformly exhibit
activation of the mTOR cascade, which contributes to the tu-
mor growth and progression. This suggests the possibility that
mTOR inhibitors, such as rapamycin or temsirolimus, may
provide therapeutic beneﬁt in the treatment of epithelioid
angiomyolipomas. A study by Ramon et al. using selective
arterial embolization showed promising results especially in
prevention of hemorrhagic complications of renal angiomyo-
lipomas and possible preservation of renal function [52].
Conclusion
Renal angiomyolipoma is an uncommon benign tumor, which
may represent a challenge for clinical and pathological diagno-
sis. Symptomatic tumors are usually 4 cm or more. The pres-
ence of fat is highly suggestive of classic AML by CT; on the
other hand, epithelioid AML contains no fat in CT and there-
fore may be misdiagnosed as RCC. AMLs are characteristi-
cally positive for HMB-45, Melan-A, and SMA and negative
for S-100 and cytokeratin.Conﬂict of interest
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